1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Coronavirus Update: 'We Are Racing Against The Virus, Not America,' Says China’s Vaccine Frontrunner

Plus: New Antibody-Focused Adagio Launched

 
• By Scrip Team

Plus new biotech company Adagio Therapeutics has been launched with a $50m series A financing to advance its coronavirus antibodies as therapeutics and prophylactics.    

Peru_Woman_Mask
Lima, Peru: the South American country's 341,000 confirmed cases to date make it the fifth worst-affected worldwide.

The head of China’s state-controlled Sinopharm Group Co. Ltd. has said its vaccine program is showing signs of good safety and efficacy as its Phase III trials progress – and has stressed that it is in a race against COVID-19, not the United States.

Yang Xiaoming, president of China National Pharmaceutical Group (Sinopharm), made the comments in an interview with China’s news outlet Global Times and also expressed confidence that its vaccine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.